<DOC>
	<DOCNO>NCT00085150</DOCNO>
	<brief_summary>RATIONALE : LMB-2 immunotoxin locate cancer cell kill without harm normal cell . PURPOSE : This phase I trial study side effect best dose LMB-2 immunotoxin treat young patient relapse refractory leukemia lymphoma .</brief_summary>
	<brief_title>LMB-2 Immunotoxin Treating Young Patients With Relapsed Refractory Leukemia Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose LMB-2 immunotoxin pediatric patient CD-25 positive relapse refractory leukemia lymphoma . - Determine toxic effect drug patient . - Determine pharmacokinetics drug , include terminal elimination serum half-life , area curve , volume distribution , relationship disease burden , patient . Secondary - Evaluate immonogenicity drug patient . - Determine response patient treated drug . - Determine change lymphocyte subset , immunoglobulin level , serum cytokine , soluble cytokine receptor level patient treat drug . OUTLINE : This dose-escalation , multicenter study . Patients receive LMB-2 immunotoxin IV 30 minute day 1 , 3 , 5 . Treatment repeat every 28 day 6 course absence disease progression , neutralize antibody ( i.e. , &gt; 75 % activity 1 µg/mL LMB-2 immunotoxin ) , unacceptable toxicity . Patients achieve complete remission ( CR ) receive 2 additional course beyond CR . Patients acute lymphoblastic leukemia also receive cytarabine hydrocortisone intrathecally monthly concurrent restaging lumbar puncture . Cohorts 3-6 patient receive escalate dos LMB-2 immunotoxin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , total 12 patient treat dose level . Patients follow weekly 1 month monthly thereafter . PROJECTED ACCRUAL : A total 20-40 patient accrue study within 2-4 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Immunotoxins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis 1 following : NonHodgkin 's lymphoma , include follow subtypes : Lymphoblastic lymphoma Burkitt 's lymphoma Large cell lymphoma Adult Tcell leukemia/lymphoma Cutaneous Tcell lymphoma Peripheral Tcell lymphoma Hodgkin 's disease Acute myeloid leukemia Chronic myelogenous leukemia Acute lymphoblastic leukemia ( ALL ) More 5 % blast bone marrow ( i.e. , M2 marrow classification ) Acute hybrid leukemia , include follow subtypes : Mixed lineage leukemia Biphenotypic leukemia Undifferentiated leukemia CD25positive ( CD25+ ) disease , meet 1 follow criterion : More 15 % malignant cell CD25+ immunohistochemistry antiCD25 antibody More 30 % malignant cell site CD25+ fluorescenceactivated cell sort analysis Measurable evaluable disease Relapsed refractory disease least 1 standard chemotherapy regimen AND 1 salvage regimen No available alternative curative therapy Ineligible refuse hematopoietic stem cell transplantation OR disease activity prohibit require time identify suitable stem cell donor No CNS leukemia lymphoma , evidence follow criterion : Cerebrospinal fluid ( CSF ) WBC &gt; 5/µl AND confirmation CSF blast Cranial neuropathy secondary underlying malignancy CNS lymphoma detect radiological imaging Prior CNS involvement current evidence CNS malignancy allow No isolate testicular ALL PATIENT CHARACTERISTICS : Age 6 month 21 year Performance status ECOG 03 ( ≥ 12 year age ) Lansky 40100 % ( &lt; 12 year age ) Life expectancy Not specify Hematopoietic Pancytopenia due disease allow For patient without bone marrow involvement : Absolute neutrophil count &gt; 1,000/mm^3 Platelet count &gt; 50,000/mm^3 ( transfusion independent ) Hepatic Bilirubin ≤ 2.0 mg/dL AST ALT ≤ 5 time upper limit normal Hepatitis B surface antigen negative Hepatitis C antibody negative Renal Creatinine clearance ≥ 60 mL/min OR Creatinine , meet follow agerelated criterion : ≤ 0.8 mg/dL ( ≤ 5 year age ) ≤ 1.0 mg/dL ( 6 10 year age ) ≤ 1.2 mg/dL ( 11 15 year age ) ≤ 1.5 mg/dL ( &gt; 15 year age ) Calcium 2.02.9 mmol/L Cardiovascular Ejection fraction ≥ 45 % MUGA OR Shortening fraction ≥ 28 % echocardiogram Pulmonary Oxygen saturation ≥ 90 % Other Sodium 130150 mmol/L Potassium 3.05.5 mmol/L Magnesium 0.51.23 mmol/L HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No clinically significant unrelated systemic illness would preclude study participation No condition would preclude study compliance No serum neutralize &gt; 75 % activity 1 μg/mL LMB2 immunotoxin tissue culture ( due either antitoxin antimouse immunoglobulin G antibody ) No active graftvshost disease ( i.e. , immunosuppression ) PRIOR CONCURRENT THERAPY : Biologic therapy Prior autologous bone marrow transplantation ( BMT ) allow At least 100 day since prior allogeneic BMT At least 1 week since prior colonystimulating factor ( e.g. , filgrastim [ GCSF ] , sargramostim [ GMCSF ] , epoetin alfa ) Chemotherapy At least 2 week since prior chemotherapy ( 4 week nitrosoureas ) except intrathecal chemotherapy No concurrent chemotherapy Endocrine therapy Concurrent corticosteroid allow provide dose stable past week increase study treatment Tapering discontinuation steroid allow Radiotherapy At least 3 week since prior radiotherapy unless &lt; 10 % marrow irradiate measurable disease exists outside radiation port Surgery Not specify Other Recovered prior therapy At least 30 day since prior investigational agent Concurrent oral supplementation maintain normal electrolyte level allow No concurrent anticoagulation therapy diseaserelated condition No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>childhood Burkitt lymphoma</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
</DOC>